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Abstract 
Cardiovascular disease is a major health problem and remains the number one cause of 
death worldwide. For centuries, medicinal plants have been used in different cultures as 
medicines for the treatment and control of various diseases. Olea africana, also known as 
the wild olive, is amongst the herbal plants used by people to treat many ailments. 
Recently, scientific studies on the hypotensive, vasodilatory and antidysarrhythmic 
effects of O. africana have been reported. Triterpenoids isolated from the O. africana 
leaves, for example, have antioxidant properties. The aqueous extract from the leaves of 
O. africana also have angiotensin-converting enzyme (ACE) inhibitory effects. ACE 
inhibitors and antioxidants protect the heart against ischemic-reperfusion injury. The 
serine / threonine protein kinase B (PKB) also known as Akt is activated downstream of 
phosphoinositide 3- (PI-3) kinase (PI-3-Kinase) and is involved in cardioprotection 
against ischemia-reperfusion injury. Angiotensin II (AII) decreases the intrinsic PI-3-
kinase activity. In this study, we hypothesized that ACE inhibitors increase PI-3-kinase 
activity and thus activates PKB. The aims of this study were: 1) to determine whether 
treatment with the crude aqueous extract of leaves of O. africana protect the heart against 
ischemic-reperfusion injury and 2) if so, to determine whether the protection is mediated 
via the PKB signaling mechanism. 
 
Hearts isolated from male Wistar rats were perfused with different concentrations of the 
plant extract. In one set of experiments, male Wistar rats were treated with the plant 
extract (1000 mg/kg/day) for 5 weeks for the evaluation of cardiac function before and 
after ischemia. At the end of the experiments, hearts were freeze-clamped and kept for 
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PKB / Akt determination. In another set of experiments, we determined the effect of O.   
africana extract (1000 mg/kg/day) or captopril (50 mg/kg/day) on infarct size. Rats fed 
jelly served as controls for captopril. In a subset of experiments, hearts were frozen 
immediately after treatment with O. africana extract (1000 mg/kg/day) or captopril (50 
mg/kg/day) and PKB were determined. 
 
Perfusion with the plant extract significantly decreased coronary flow (p<0.05). The heart 
function was decreased as evidenced by observed decreases in the force of contraction 
and heart rate, although these were not measured. Chronic treatment with the crude 
aqueous plant extract had no effect on cardiac function before ischemia, functional 
recovery (% left ventricular developed pressure and % rate pressure product) and PKB / 
Akt phosphorylation (p>0.05). Both the aqueous extract of O. africana leaves and 
captopril had no effect on infarct size compared to the control group (p>0.05). Captopril, 
however, improved the recovery of the left ventricular developed pressure. Non-perfused 
hearts isolated from rats treated with O. africana extract and captopril did not show any 
response to both captopril and the O. africana extract treatment as measured by PKB / 
Akt phosphorylation. The results of the present study suggest that the crude aqueous 
extract of O. africana is not cardioprotective against ischemia-reperfusion injury in this 
system of the isolated perfused rat heart.  
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CHAPTER 1 
INTRODUCTION 
 
Cardiovascular disease is a major health problem worldwide and remains the number one 
cause of death (http://www.who.org, June 2009). According to the World Health 
Organization (WHO), approximately 17.5 million people died from cardiovascular 
disease in 2005, representing 30% of all global deaths. Of these deaths, 7.6 million were 
due to heart attacks and 5.7 million due to stroke. It is estimated that around 80% of these 
deaths occurred in low and middle income countries (http://www.who.org, June 2009). 
The increased prevalence of cardiovascular disease has serious socioeconomic 
consequences. About 84% of the world’s populations are in the middle and lower income 
classes (www.worldbank.org, 23 June 2009) and because clinical care of cardiovascular 
disease is costly and prolonged, there is a need to look at other medicines that will be 
easily accessible, less costly and have fewer side effects.  
 
Medicinal plants play a key role in the global health issues. For centuries, medicinal 
plants have been used in different cultures as medicine for the treatment of various 
diseases. It is estimated that 65-80% of the world’s population who lives in developing 
countries use plants for primary health care and this dependency is mainly due to poverty 
and lack of access to modern medicine (Akerele, 1993; Wood-Sheldon et al., 1997). In 
many remote areas in African countries, people consult the traditional healer of the 
village to deal with cases of illness. Hospitals and medicines are often beyond their reach 
and western medicine is too expensive (Wood-Sheldon et al., 1997). Scientific interest in 
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medicinal plants has grown rapidly due to increased effectiveness of new plant-derived 
drugs and rising concerns about the side effects of conventional medicine (Lee, 2004).  
 
Olea africana, also known as the wild olive, is one of the herbal plants used by people for 
various illnesses. In southern Africa, the wild olive has been chosen amongst 120 plant 
species to be the most important plant in use in traditional medicine (Dold and Cocks, 
1999). The beneficial effects of the wild olive on the cardiovascular system have been 
previously documented (Khayyal et al., 2002; Osim et al., 1999; Somova et al., 2003; 
Zarzuzelo et al., 1991). Hypotensive effects of O. africana (Khayyal et al., 2002; Osim et 
al., 1999; Somova et al., 2003) as well as vasodilatory effects (Zarzuzelo et al., 1991) 
have been reported. Likewise, the isolates (oleanolic acid, ursolic acid and uvaol) from 
the same plant have been shown to have anti-arrhythmic effects (Somova et al., 2004). 
Triterpenoids, namely oleanolic acid and ursolic acid, isolated from the O. africana 
leaves are known to have antioxidant properties (Somova et al, 2003). The aqueous 
extract from the leaves of O. africana have angiotensin converting enzyme (ACE) 
inhibitory effects (Adersen et al., 1997; Hansen et al., 1996). ACE inhibitors (Ozer et al., 
2002; Eichhorn, 1998; Maulik et al., 2001; Takeda et al., 1997) and antioxidants 
(Venardos et al., 2004; Dhalla et al., 2000; Marczin et al., 2003) protect the heart against 
ischemic-reperfusion injury.  
 
The serine / threonine kinase, PKB, also known as Akt, is a key mediator of many signal 
transduction process. PKB / Akt is involved in cardioprotection against ischemia-
reperfusion injury and is activated downstream of phosphoinositide 3- (PI-3) kinase 
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(Engelbrecht et al., 2006). PI-3-kinase consists of an 85-kDa regulatory subunit (p85) and 
a 110-kDa catalytic subunit (p110). Angiotensin II (AII) increases phosphorylation of 
p85 and decreases the intrinsic PI-3-kinase activity associated with the p85/p110 complex 
(Folli et al., 1997). In this study, we hypothesized that ACE inhibitors, by decreasing AII 
levels, increase PI-3-kinase activity and thus activates PKB. We therefore assumed that 
O. africana by virtue of its ACE inhibitory properties will activate PKB.   
 
Several studies have concentrated on the cardiovascular effects of O. africana, but none 
on the potential cardioprotection by Olea africana following ischemia-reperfusion injury. 
The present study was undertaken to evaluate the cardiovascular effects of a crude 
aqueous extract of O. africana leaves against ischemia-reperfusion injury on the isolated 
perfused rat heart. 
  
The objectives of the study were to: 
1. Determine whether treatment with the crude aqueous extract from leaves of O. 
africana protects the isolated rat perfused heart against ischemia-reperfusion 
injury. 
2. Evaluate whether the protection referred to above is mediated via PKB signaling.  
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CHAPTER 2 
LITERATURE RIVIEW 
 
2.1 Use of plants in traditional medicine 
 
Medicinal plants play a key role in world health. A medicinal plant is any plant which 
provides health-promoting characteristics or curative properties. Plant parts used include 
seeds, berries, roots, leaves, bark and flowers. For centuries, medicinal plants have been 
used in different cultures as medicine for the treatment of various diseases. Garlic (Allium 
sativum) has been used traditionally to treat cramps, worm infestation, hypertension, high 
cholesterol levels and warts (Banerjee et al., 2002). Aloe vera has been applied externally 
for the healing of burns and wounds (Maenthaisong et al., 2007). Rooibos (Aspalathus 
linearis) has been reported to cure skin ailments, allergies, asthma and colic in infants 
(Joubert et al., 2008). Calendula (Calendula officinalis) has been used to treat abdominal 
cramps and constipation (Bashir et al., 2006). Indian Snakeroot (Rauvolfia serpentina) 
has been used in India to treat insomnia, anxiety and high blood pressure (Sukh, 1999)
 
.  
It is estimated that around 80% of the world’s population (Wood-Sheldon et al., 1997), 
80-90% of the population in African countries (Hostettman et al., 2000) and 27 million 
people in South Africa (Meyer et al., 1996; Mander, 1998) depend on traditional 
medicine for primary health care. The use of various herbal remedies and preparations are 
described throughout human history representing the origins of modern medicine. Many 
conventional drugs originate from plant sources, such as aspirin derived from bark of 
willow, digoxin derived from foxglove, quinine derived from the bark of cinchona and 
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morphine derived from the opium poppy (Lee, 2004). Scientific interest in medicinal 
plants has grown and expanded rapidly due to an increased effectiveness of new plant-
derived drugs and rising concerns about the side effects of conventional medicine (Lee, 
2004). Plant constituents or ingredients vary considerable depending on several factors 
that affect the quality of a traditional medicine. These include environmental factors such 
as type of the soil, altitude and climate. Other factors that affect the quality of a 
traditional medicine are the use of fresh plants, water availability, period (season), time of 
collection, method of collecting, drying, storage, age and part of the plant collected.  
 
2.2 Traditional plants with cardiovascular effects 
 
2.2.1 Ginseng  
 
Ginseng (Panax ginseng) is a root of the perennial herb which contains a series of 
tetracyclic triterpenoid saponins (ginsenosides) as active ingredients (Nocerino et al., 
2000). The English word “ginseng” is derived from the Chinese term, renshen, meaning 
“man root”. Red ginseng has been used as an antihypertensive agent in Korea (Braun et 
al., 2007) and, in animal studies, Panax ginseng was shown to decrease blood pressure 
(Morgan et al., 2000). The hypotensive effects of ginseng is claimed to be due to an 
angiotensin–converting enzyme (ACE) inhibitory effect (Persson et al., 2006) and also 
due to nitric oxide (NO) release stimulated by ginsenosides (Morgan et al., 2000). Nitric 
oxide in turn causes smooth muscle relaxation and vascular dilation (Morgan et al., 
2000). Red ginseng powder reduces plasma total cholesterol and triglycerides while 
elevating high density lipoproteins (HDL) (Yamamoto et al., 1983).  
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2.2.2 Garlic 
Garlic (Allium sativum L) is a perennial plant of the Alliaceae family, which includes 
onion, chive, shallot and leek. Allicin, the major component present in freshly crushed 
garlic, is one of the most biologically active compounds of garlic (Zhang et al., 2001). 
Garlic extracts have been widely recognized as agents for the prevention and treatment of 
atherosclerosis, hyperlipidemia, thrombosis, hypertension and diabetes (Banerjee et al., 
2002
 
). 
Garlic's ability to significantly lower total blood cholesterol has been shown in many 
studies, suggesting that it may provide some protection against coronary artery disease 
and stroke (Auer et al., 1990; Jain et al., 1993; Warshafsky et al., 1993). A more recent 
meta-analysis of placebo controlled trials using standardized dried garlic powder showed 
a significant reduction in total cholesterol levels, low density lipoprotein and triglycerides 
levels at 8-12 weeks (Ackermann et al., 2001). Clinical studies have also shown that 
garlic has antihypertensive effects, decreasing both the systolic and diastolic pressures 
(Banerjee et al., 2002). Garlic has also been found to decrease platelet aggregation 
(Rahman, 2007; Steiner et al., 1998). 
 
Chronic oral administration of garlic extract prevents 
oxidative stress and ultrastructural changes induced by myocardial ischemia-reperfusion 
injury (Banerjee et al, 2002). 
2.2.3 Hawthorn   
Hawthorn (Crataegus species) is an aromatic, sweet and sour herb that belongs to a 
member of the Rosaceae family. It contains oligomeric procyanidins, flavanoids, 
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chlorogenic, caffeic acid and triterpenes (Leung et al., 2008). Hawthorn extracts from the 
leaves, berries and flowers are one of the safer remedies.  In the 19th
 
 century, hawthorn 
berries have been used in Western Europe as a cardiotonic and are a recognized treatment 
for heart failure (Fugh-Berman, 2000). In clinical studies conducted on people with heart 
failure, hawthorn significantly improved heart function (Degenring et al., 2003; Zapfe, 
2001). Animal and laboratory studies demonstrate that hawthorn has antioxidant 
properties that protects against the formation of atherosclerotic plagues (Bahorun et al., 
1994). The hawthorn extract administered intravenously in rats produced hypotensive 
effects by reducing mean arterial pressure (Leung et al., 2008).  
2.2.4 Ginkgo  
Ginkgo (Ginkgo biloba), also known as the Maidenhair tree, is a unique species with no 
living relatives. The leaf extract has been used for more than 3000 years by the Chinese 
and is the best selling remedy in the United States (Khan et al., 2006). It is believed to be 
rich in flavanoids and triterpenoids which exert their effects through free radical 
scavenging, antiplatelet activity, vasodilation, decreasing blood viscosity and anti-
inflammatory activity (Khan et al., 2006). Ginkgo decreases platelet aggregation and 
causes vaso-relaxation by blocking nitric oxide metabolism (Gold and Farnsworth, 2002). 
Results from clinical trials demonstrate that a standardized leaf extract of Ginkgo is 
useful in preventing and treating cardiovascular disease (CVD), particularly ischemic 
cardiac syndromes (Mahad, 2002).  
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2.2.5 Soy 
Soybean (Glycine max) is a legume native to East Asia. It has been used in China for 
5000 years as a food and a component of drugs (Derbyshire et al., 1976). It contains 
significant amounts of amino acids essential for humans, and it is a good source of 
protein. In clinical trials, soy products consumption reduced total cholesterol and low 
density lipoprotein cholesterol (LDL-C) levels (Hasler, 2002).  
 
2.3 Plants that protect against ischemia-reperfusion injury 
 
Chronic oral administration of garlic extracts (25, 250 and 500 mg/kg) prevent oxidative 
stress by decreasing thiobarbituric acid reactive substances (TBARS), depletion of 
endogenous antioxidants (catalase, superoxide dismutase and glutathione) and 
ultrastructural changes induced by myocardial ischemia-reperfusion injury (Banerjee et 
al., 2002). Acute treatment with bagflower (Clerondendron colebrookianum) aqueous 
extracts (0.01% and 0.05%) administered at the time of reperfusion protects against 
oxidative stress and cellular injury associated with ischemia-reperfusion injury (Devi et 
al., 2005). The aqueous extracts from guava (Psidium guajava) and sea lavender 
(Limonium wrightii) have cardioprotective effects against myocardial ischemia-
reperfusion injury in isolated rat hearts, primarily through their free radical-scavenging 
actions. The extracts attenuate ischemic contracture during ischemia and improved 
myocardial dysfunction after reperfusion (Yamashiro et al., 2003).  
 
 
 
 
 
 
 
 
 
 9 
2.4 Olea africana 
 
Olea europaea, subspecies africana, also known as the wild olive is a species belonging 
to the family Oleaceae (Green et al., 1979; Van Wyk et al., 1997). The wild olive is 
mainly located in Africa. In history, the wild olive is one of the most quoted in literature 
(Verdoorn, 1963). The olive fruit is of major agricultural importance in the 
Mediterranean region as a source of olive oil.  In Southern Africa, the wild olive is one of 
the most popular plants used by Sotho, Xhosa and Zulu tribes (Watt and Breyer-
Brandwijk, 1962; Hutchings, 1989 and Van Wyk and Gerike, 2000). Of 120 species, 
umNquma (wild olive) was designated the most important plant in traditional medicine 
(Dold and Cocks, 1999).  
 
2.4.1 Vernacular names of the plant 
The wild olive is named umNquma (Xhosa), Isadlulambazo (Zulu), Motholoari (Sotho) 
(Watt and Breyer-Brandwijk, 1962; Hutchings, 1989; Van Wyk and Gerike, 2000),  
Mutlhwari (Venda), Motlhware (Tswana) and Swartolienhout (Afrikaans) Green et al., 
1979. 
 
2.4.2 General description 
 The wild olive is a neatly shaped evergreen tree with a dense spreading crown (9 x 12 m) 
of glossy grey-green to dark-green foliage. Leaves are grey-green to dark-green above 
and greyish below. The tiny, lightly scented white to greenish flowers spray from 
October to February, followed from March to July with small, spherical, fleshy fruits, 
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either sweet or sour, which ripen purple-black (Green et al., 1979). The olive tree grows 
in the wide variety of soils with marked preference for calcareous (containing calcium 
carbonate, calcium, limestone and chalky) soil and coastal climate conditions. The tree is 
very tolerant to drought and high pH (Green et al., 1979). 
 
 
Figure 2.1: O. africana plant 
(From: Green et al., 1979) 
 
2.4.3 Traditional medicinal uses 
 Infusions prepared from the leaves of O. africana are used to treat eye infections or as a 
gargle to relieve sore throat (Green et al., 1979). The infusion is also taken internally as a 
remedy for colic or urinary tract infection and to improve kidney function. The powdered 
leaf is used as a styptic. The fruit is used to treat diarrhoea (Green et al., 1979). 
Traditional remedies prepared from the leaves, roots or stem bark are used to lower blood 
pressure and to treat related cardiovascular diseases (Watt, 1962; Hutchings, 1996).  
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2.4.4 Bioactive compounds in the olive leaf   
The active ingredients found in the plant are chemical compounds that are responsible for 
the specific activity of the plant by acting directly or indirectly to prevent or treat disease 
and maintain health. 
 
2.4.4.1 Phenolic compounds 
Oleuropein, a member of secoiridoids, is the major principal phenolic compound present 
in the leaves of the plant. Bourquelot and Vintilesco (1908) isolated the compound which 
is a heterosidic ester of oleanolic acid and hydroxytyrosol. The oleuropein content in the 
olive leaves was found to be high, around 60 - 90 mg per gram of the dry material (Le 
Tutour et al., 1992).   
 
 
Figure 2.2:  Chemical structure of Oleuropein 
(From: Andreadou et al., 2006) 
 
Other phenolic compounds have been isolated and identified in the olive leaves through 
the process of hydrolysis but are present in lesser quantity. These compounds include 
demethyloleuropein, ligstroside (Soler-Rivas et al., 2000), verbascoside (Amiot et al., 
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1986). Flavanoids, another group of phenolic compounds found in the olive leaves are 
luteolin-7-0-glucoside, luteolin-7-0-rutinoside, apigenin-7-0-glucoside, rutuin, luteolin 
and apigenin (De Laurentis, 1997). 
 
2.4.4.2 Terpenic compounds 
Another group of bioactive compounds found in the olive leaf is terpenic compounds 
(Khan et al., 2007). Mussini et al. (1975) isolated alpha-amyrine and confirmed the 
presence of maslinic acid. Oleanolic acid (3-beta-hydroxyoleon), found extensively 
throughout the plant kingdom, is another terpenic compound found in the olive leaf. 
Oleanolic acid in the olive leaf occurs in free acid form accounts for 3% of the dry leaf 
weight (Khan et al., 2007). 
 
2.5 Toxicity of the plant 
The triterpenoids, oleanolic acid (OA) and ursolic acid (UA) isolated from African wild 
olive leaves have low toxicity on brine shrimps, LC50 0.10 mg/ml (OA) and 0.95 mg/ml 
(UA) (Somova et al., 2003). The crude aqueous extract of the same plant have low 
toxicity-LC50 
 
> 5000 µg/ml (Wang, 2008).  
2.6 Cardiovascular effects of Olea africana 
In an isolated perfused rabbit heart using the Langendorff system, the ethanol extract 
from the leaves of Olea europaea decreased systolic pressure, heart rate and caused an 
increase in relative coronary flow (ratio between coronary flow and rate pressure product) 
(Scheffler et al., 2008). Using the same extract in cultured neonatal rat cardiomyocytes, 
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the extract caused a significant decrease in maximum L-type calcium channel (Ica.L
 
) peak 
currents and this was reversible upon washout (Scheffler et al., 2008).  
2.6.1 Antihypertensive / hypotensive effects 
The triterpenoids namely oleanolic acid and ursolic acid, isolated from Olea africana 
leaves were reported to have antihypertensive and anti atherosclerotic effects. The effects 
were studied on the Dahl salt-sensitive (DSS) and insulin-resistant genetic rat model of 
hypertension (Somova et al., 2003). Ribeiro et al. (1986) showed that a crude aqueous 
ethanol (50:50 volume) extract of the olive leaves when given orally at a dose of 40 
ml/kg produced antihypertensive effects in spontaneous hypertensive rats. Osim et al. 
(1999) reported the hypotensive effects of the crude aqueous and ethanol extracts in 
normo and hypertensive rats. The aqueous extract was more potent than the ethanol 
extract. Oral administration of the extract (100 mg/kg) in hypertensive rats was shown to 
have antihypertensive effects (Khayyal et al., 2002). 
 
Zarzuelo et al. (1991) reported vasodilatory effects of a decoction made from Olea 
europaea leaf on isolated rat aorta preparations. Oleuropeoside was shown to be the 
active compound responsible for the vasodilatory action. The aqueous leaf extract of 
Olea africana was found to posses ACE inhibitory effects, inhibiting ACE activity by 
82% (Adersen et al., 1997). Using whole blood from normotensive and hypertensive rats, 
the crude aqueous extract of the same plant caused a decrease in ACE levels and 
prevented hypertension from Dahl salt-sensitive rats by decreasing plasma angiotensin II 
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levels (Wang, 2008). In O. europaea aqueous leaf extract, Oleacein was shown to be an 
active ingredient responsible for the ACE inhibitory activities (Hansen et al., 1996).  
 
2.6.2 Antidysrhythmic effects 
Somova et al. (2004) examined the cardiotonic and antidysrhythmic activity of the 
triterpenoids, namely, oleanolic acid, ursolic acid and uvaol isolated from leaves of the 
Africana wild olive and methyl maslinate isolated from leaves of Olea europaea. 
Arrhythmias were chemically induced with calcium chloride and adrenaline, and 
mechanically induced through ischemia-reperfusion. The isolates showed 
antidysrhythmic activity on both the chemical and mechanical types of arrhythmia and 
displayed a significant dose-response vasodepressor effect and sinus bradycardia. 
 
2.7 Ischaemic-reperfusion injury 
Ischemia-reperfusion represents a clinically relevant problem associated with 
thrombolysis, angioplasty and coronary bypass surgery (Dhalla et al., 2000). Ischemia is 
described as an inadequate flow of blood to the myocardium due to constriction of the 
blood vessels supplying the heart muscle. Myocardial ischemia can result in tissue 
damage leading to necrosis and apoptosis. Restoration of blood flow (reperfusion) is the 
only way to save the myocardium from eventual tissue death, however, reperfusion has 
been shown to exacerbate myocardial damage (Takeda et al., 1997; Ozer et al., 2002; 
Narang et al., 2004). Myocardium ischemia-reperfusion injury includes contractile 
dysfunction, arrhythmias and irreversible myocyte damage (Dhalla et al., 2000). The 
changes in the myocardium due to ischemic-reperfusion injury are considered to be due 
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to increase formation of reactive oxygen species (ROS), calcium (Ca2+
 
) overload and the 
activation of the renin-angiotesin system (Liang, et al., 1981; Wang et al., 2001; Murphy 
and Steenbergen, 2008).  
Oxidative stress has been largely implicated in the etiopathogenesis of ischemic-
reperfusion injury as evidenced by increase in thiobarbituric acid reactive substances 
(TBARS) and depletion of endogenous antioxidants (Narang et al., 2004; Devi et al., 
2005; Vanden Hoek et al., 1997; Marczin et al., 2003, Dhalla et al., 2000; Benerjee et al., 
2002, Jan-Kan et al., 2005; Venardos et al., 2004). During reperfusion, oxygen undergoes 
sequential reduction to form reactive oxygen species (ROS) such as superoxide radical, 
hydrogen peroxide (H2O2) and hydroxyl radical (Banerjee et al., 2002; Dhalla et al., 
2000; Narang et al., 2004). Due to increased ROS production, the antioxidant defense 
mechanism is overwhelmed resulting in an imbalance between oxidants and endogenous 
antioxidant defense mechanisms, causing oxidative stress (Molyneux et al., 2002; 
Marczin et al., 2003; Vanden Hoek et al., 1997). Oxidative stress modifies phospholipids 
and proteins leading to lipid peroxidation and oxidation of thiol groups which alter 
membrane permeability. The alteration in membrane permeability may result in cellular 
defects, including a depression in the sarcolemmal Ca2+ ATPase and Na+-K+ ATPase 
pumps, which leads to decreased Ca2+ efflux and increased Ca2+ influx in cardiac cells. 
The depression in Ca2+ regulatory mechanism by ROS ultimately results in intracellular 
Ca2+ overload (Dhalla et al., 2000). A rise in Ca2+ leads to activation of calpains, which 
may be involved in the cleavage of proteins resulting in plasma membrane rupture and 
activation of pro-apoptotic BID, thus resulting in apoptotic cell death. Also, an increase 
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in Ca2+
 
 leads to activation of inner mitochondrial large-conductance channel, MPT, 
which leads to loss of ATP and mitochondrial function, resulting in mitochondrial 
swelling and the release of cytochrome c, thus activating apoptosis (Murphy and 
Steenbergen, 2008). 
 
 
Figure 2.3: Pathophysiologic implications of oxidative stress in    
ischemia-reperfusion injury in the heart 
(From: Dhalla et al., 2000) 
 
In addition to ROS, oxidative stress may also be caused by nitrogen oxygen species. 
Peroxynitrite (ONOO−), a nitrogen oxide species, has also been shown to cause 
deleterious effects in the heart following ischemia and reperfusion (Dhalla et al., 2000). It 
is formed by fast biradical reaction of nitric oxide and superoxide anion, mainly in the 
vascular endothelium, myocytes and neutrophils. Peroxynitrite hydroxylates, nitrates 
aromatic and compounds induce cellular damage by lipid peroxidation, DNA 
fragmentation, damage of proteins and plasma lipids, depleting antioxidants such as 
glutathione and cysteine and nitrating proteins leading to cellular and organ dysfunction, 
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thus resulting in cell death (Ronson et al., 1999). Peroxynitrite induces apoptotic cell 
death in a variety of cell types in culture such as pheochromocytoma-derived PC12 cells, 
cortical neurons, HL-60 cells and rat thymocytes (Wang et al., 2007).  
 
Specific proteases that belong to the caspase family are crucial effectors of apoptosis. In 
response to an apoptotic stimulus (i.e. ROS), activation of the pro-apoptotic Bcl-2 family 
members such as BAD, Bak and Bax trigger a sequence of events leading to the release 
of mitochondrial cytochrome c into the cystol. Cytochrome c forms a complex with, 
dATP, pro-caspases and Apaf-1, resulting in activation of caspase 9, and then caspase 3. 
Once activated, caspase 3 cleaves poly ADP ribose polymerase (PARP) and induces 
cytoplasmic and nuclear apoptosis, including DNA fragmentation (Hausenloy et al., 
2004; Castanenda et al., 2003; Kumar and Jugdutt, 2003). Mitochondrial dysfunction also 
causes release of an alternative protein (apoptosis inducing factor, AIF), which activates 
caspase 3 for the initiation of apoptotic pathway. 
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Figure 2.4: Oxidative stress-induced apoptotic pathways involved in the 
heart disease 
(From: Kumar and Jugdutt, 2003) 
 
The rennin-angiotensin system (RAS) is known to be involved in the pathogenesis of 
ischemia-reperfusion induced myocardial injury (Liang, et al., 1981; Wang et al., 2001; 
Ferreira et al., 2007). Activation of RAS leads to increased formation of Angiotensin II, 
which, in turn, causes vasoconstriction, reperfusion arrhythmias and generation of 
oxygen free-radicals resulting in increased ischemic-reperfusion injury (Maulik et al., 
2001). Angiotensin II increases intracellular calcium levels of myocytes and smooth 
muscle cells through activation of ryanodine–sensitive Ca2+ release channels in the 
sarcoplasmic reticulum (SR), leading to positive inotropism, impairment of diastolic 
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function and coronary vasoconstriction. At pathophysiological levels, angiotensin II is 
cardiotoxic and induces myocyte death (Moens et al., 2005). 
 
2.8 Mechanisms that protect the heart against ischemia-reperfusion 
injury 
 
Angiotensin converting enzyme (ACE) inhibitors protect against ischemia-reperfusion 
injury (Maulik et al., 2001; Ozer et al., 2002; Takeda et al., 1997; Linz et al., 1986; De 
Graeff et al., 1984). Antioxidants through their free radical scavenging effects inhibit the 
generation of reactive oxygen species and reduce injury associated with ischemia-
reperfusion (Moens et al., 2005; Banerjee et al., 2205; Dhalla et al., 2000; Andreadou et 
al., 2006; Jan-Kan et al., 2005; Marczin et al., 2003; Venardos et al., 2004; Banerjee et 
al., 2002). Endogenous antioxidants such as superoxide dismutase (SOD), catalase (CAT) 
and glutathione peroxidase (GPx)  are  the major antioxidant defense mechanisms in the 
heart and have a protective function in maintaining thiol groups of enzymes and other 
proteins in their reduced state and in preventing peroxidation of membrane lipids 
(Molyneux et al., 2002).   
 
Activation of the prosurvival kinases such as Akt and Erk 1/2 which are termed 
reperfusion injury salvage kinase (RISK) pathway has been demonstrated to confer 
powerful cardioprotection against myocardial ischemia-reperfusion injury (Haunseloy et 
al., 2004; Haunseloy et al., 2005; Engelbrecht et al., 2006; du Toit et al., 2008). The 
RISK pathway is activated down stream of phosphatidylinositol-3-OH kinase (PI3-K). 
The pathway has been implicated in cellular survival through recruitment of anti-
apoptotic pathway of protection (Haunseloy et al., 2004). Activation of Akt or Erk 1/2 
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cascades phosphorylate the pro-apoptotic protein BAD. Phosphorylation of BAD results 
in its binding to 14-3-3 proteins, which confiscate it from its mitochondrial targets, 
thereby preventing apoptosis. Also, phosphorylation of Akt or Erk 1/2 inhibits 
conformational changes in BAX required for its translocation to the mitochondria, 
thereby preventing apoptosis. ACE inhibitors (Frolkis et al., 2001), antioxidants 
(Onimaru et al., 2006) and the RISK pathway (Akt and Erk 1/2) (Hausenloy et al., 2005) 
prevent cell death by inhibiting factors that mediate apoptosis and necrosis (ROS and 
AII). 
  
2.9 ACE inhibitors and ischemia-reperfusion 
Clinical and experimental studies have established the therapeutic benefits of ACE 
inhibitors not only in treating hypertension and congestive heart failure but also in 
reducing reinfarction (Eichhorn, 1998), limiting infarct size (Liu et al., 1996; Ozer et al., 
2002) and reducing reperfusion arrhythmias (Ozer et al., 2002, Olmez et al., 1995; 
Westlin et al., 1998; van Gilst et al., 1986). The beneficial effects of ACE inhibitors are 
mediated through vasodilation by preventing or reduction in both local AII generation 
and bradykinin degradation (Ferreira et al., 2007; Ozer et al., 2002). ACE inhibitors 
facilitate salt and water excretion by complex effects on the kidney and these include 
attenuation of secondary hyperaldosteronism with a reduction in mineralocorticoid-
stimulated sodium reabsorption. ACE inhibitors also inhibit angiotensin-mediated thirst 
by an action on the hypothalamus. The attenuation of aldosterone effects reduces 
hypokalemia, and this may contribute to the antiarrythmic effect of ACE inhibitors 
(Fletcher, 1996). 
 
 
 
 
 21 
In an in vivo model of myocardial ischemia-reperfusion injury, acute treatment with 
captopril (4 mg/kg), an ACE inhibitor, when administered before ischemia rather than 
before reperfusion prevents loss of haemodynamic function (LVDEP and MAP), rise in 
TBARS and depletion of endogenous antioxidants (glutathione, superoxide dismutase 
and catalase) (Maulik et al., 2001). Similarly, using the isolated perfused heart, acute 
treatment with captopril (8 µg/ml or 80 µg/ml) for few minutes before ischemia and 
during the first few minutes of reperfusion improved post-ischemic cardiac function (rate 
pressure product and coronary flow) and levels of adenosine triphosphate (ATP), 
adenosine diphosphate (ADP) and creatine phosphate (CrP) (Takeda et al., 1997). Using 
an in vivo model of myocardial ischemia-reperfusion injury, acute treatment with 
captopril (3 mg/kg) before ischemia reduced the incidences of ventricular fibrillation and 
myocardial infarct size (Ozer et al., 2002).  
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2.10 PKB / Akt pathway 
 
 
Figure 2.5: Schematic representation of the PI-3 kinase-PKB / Akt 
signaling pathway 
(From: www.cellsignal.com, Feb 2010) 
 
The serine / threonine protein kinase B also known as Akt is a key mediator of signal 
transduction (cell proliferation, survival and apoptosis) processes (Lawlor et al., 2001). 
The protein has three isoforms, namely, Akt1 / PKB-alpha, Akt2 / PKB-Beta and Akt3 / 
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PKB-gamma. Akt has three domains, the N-terminal pleckstrin homology (PH) domain, a 
kinase domain and a C-terminal regulatory domain. The binding of ligands such as 
growth factors, cytokines, mitogens, insulin or insulin like growth factors and hormones 
to the receptor tyrosine kinase (RTK) in the cell membrane results in autophosphorylation 
of tyrosine residues on the intracellular domain of the receptor. Phosphoinositol 3-kinase 
(PI-3-kinase) which consists of an 85-kDa regulatory subunit (p85) and a 110-kDa 
catalytic subunit (p110) is then recruited to the phosphotyrosine residues via Src 
Homology 2 (SH2) domains in the regulatory subunit. The binding of the p85 subunit to 
the phosphorylated RTK leads to conformational change in the catalytic subunit and 
consequent kinase activation (Brar et al., 2002). PI-3-kinase phosphorylates membrane 
bound phosphatidylinositol-4,5-diphosphate (PIP2) to produce phosphatidylinositol-
3,4,5-triphosphate (PIP3) and this can be reversed by phosphatase and tension homology 
(PTEN). The binding of PIP3 to the pleckstrin homology (PH) domain of Akt anchors 
Akt to the plasma membrane and allows its phosphorylation ( at T308 and S473 sites) 
and activation by phosphoinositide–dependent kinases (PDK-1 and PDK-2) (Anderson et 
al., 1998). Akt mediate many of the downstream events (protein synthesis, survival, 
proliferation and glucose metabolism) regulated by PI-3-kinase. PKB / Akt protein kinase 
promotes cell survival by inhibiting proteins that mediate apoptosis, such as the Bcl2 
family member BAD and the Forkhead family of transcription factors. BAD promotes 
apoptosis by interacting with Bcl-XL on the mitochondrial membrane. Phosphorylation of 
BAD by PKB enables it to interact with 14-3-3 proteins which prevent it from binding to 
Bcl-XL, thereby preventing apoptosis (Lawlor et al., 2001). Akt regulates cell growth 
through its effects on the mTOR and p70 S6 kinase pathways, the cell cycle and cell 
 
 
 
 
 24 
proliferation through its direct action on the CDK inhibitors p21 and p27, and its indirect 
effect on the levels of cyclin D1 and p53 (Manning and Cantley, 2007). Akt has been 
shown to regulate proteins involved in neuronal function including GABA receptor, 
ataxin-1 and huntingtin proteins (Manning and Cantley, 2007). 
 
2.10.2 PKB / Akt in ischemia-reperfusion  
In response to ischemia-reperfusion-induced injury, several signal transduction pathways 
in the heart are triggered (Engelbrecht et al., 2006). The PI-3-kinase-PKB / Akt pathway 
is activated in response to ischemia-reperfusion injury and initiate myocardial protection 
through its anti-apoptotic action (Haunseloy et al, 2004). Activation of PKB via PI-3-K 
inase has been shown to protect cells against hypoxia / reoxygenation induced cell death 
(Brar et al., 2002). PKB / Akt promotes survival of cardiomyocytes in vitro and protects 
against ischemia-reperfusion injury in the mouse heart (Fujio et al., 2000). Haunseloy et 
al. (2005) has shown that activation of prosurvival kinase PKB / Akt in both pre-
conditioning and post-conditioning to be cardioprotective against myocardial ischemia-
reperfusion injury.  
  
2.11 Research problem 
 The aqueous extract of the leaves of O. africana has angiotensin converting enzyme 
(ACE) inhibitory properties (Adersen et al., 1997; Wang, 2008). The triterpenoids 
isolated from the O. africana leaves have also been shown to have antioxidant properties 
(Somova et al, 2003). ACE inhibitory and antioxidants properties are noteworthy since 
ACE inhibitors (Ozer et al., 2002; Eichhorn, 1998; Maulik et al., 2001; Takeda et al., 
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1997) and antioxidants (Venardos et al., 2004; Dhalla et al., 2000; Marczin et al., 2003) 
protect the heart against ischemia-reperfusion injury.  
 
To our knowledge, there is currently no study in which cardioprotection by Olea has been 
demonstrated in ischemia-reperfusion injury. Therefore, the present study aims to 
investigate the cardioprotective effects of O. africana in ischemia-reperfusion injury. The 
PKB / Akt pathway which is involved in cardioprotection against ischemia-reperfusion 
injury (Haunseloy et al., 2004; Haunseloy et al., 2005, Fujio et al., 2000), is activated 
downstream of PI-3-kinase (Engelbrecht et al., 2006). Angiotensin II decreases the 
intrinsic PI-3-kinase activity (Folli et al., (1997)). Furthermore, Wang (2008) showed that 
the crude aqueous extract of the O. africana leaves decrease plasma AII levels in 
hypertensive rats. We therefore hypothesized that ACE inhibitors increase PI-3-kinase 
activity and thus activate PKB. Based on our hypothesis on ACE inhibitors, we will also 
determine whether the protection is mediated via the PKB / Akt signaling mechanism, 
since the aqueous extract of O. africana has ACE inhibitory effects (Adersen et al., 1997; 
Wang, 2008). O. africana is traditionally used with hot water as a tea, hence it is 
important for the aqueous extract to be considered.                                                                                                                                                                                                                                                                                                                             
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CHAPTER THREE 
 
MATERIALS AND METHODS 
 
 
3.1 Preparation of the extract 
 
Fresh leaves of Olea europaea subsp. africana were collected between April and May 
2006 at the University of the Western Cape (UWC) and ground powder from the leaves 
collected in June 2006 were bought from Parceval pharmaceutical company in Cape 
Town, South Africa. The leaves that were harvested at UWC were identified by Mr Frans 
Weitz of the Department of Botany. The leaves were washed and air-dried for three 
weeks. The dried leaves were milled to a fine powder. The aqueous extract was obtained 
by shaking the powder (100 g) in distilled water (900 ml) and allowing the mixture to 
stand for 24 hours before filtering. The filtrate was frozen overnight at -80 °C and freeze 
dried until a fine powder was obtained. The freeze dried powder was stored in a sealed 
container and kept in the fridge.   
 
3.1.1 Toxicity test 
Toxicity of the aqueous extract of Olea africana was investigated using the brine shrimp 
(Artemia salina) toxicity test, according to the method of Meyer et al. (1982). Artemia 
eggs (30 – 40 g) obtained from a local pet shop were hatched in a 1-liter bottle filled with 
fresh filtered sea water.  The eggs were kept under constant aeration at 30 °C until the 
eggs were fully hatched. After hatching, 100 µl containing between 10 - 20 active nauplii, 
was transferred to petri dishes containing sea water and different concentrations of the 
extract  and made up to a final volume of 5000 µl with sea water. The toxicity of the 
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plant extract was determined in duplicates using nine concentrations: 2.5, 10, 25, 50, 250, 
750, 1250, 1750 and 2250 mg/ml. To account for accidental deaths, controls without 
extract were included. The petri dishes were maintained at room temperature for 24 hours 
under a light. For each petri dish, the number of larvae were recorded. After 24 hours, the 
number of surviving larvae were counted and the percentage deaths at each concentration 
were determined.  
 
LC50 
The percentage mortality was plotted against the O. africana concentration. The LC
determination 
50 
 
value (value which causes 50% mortality) was obtained by regression analysis. 
3.2 Chemicals and drugs  
Sodium chloride, sodium bicarbonate, potassium chloride, potassium di-hydrogen 
phosphate, magnesium sulphate, sodium sulphate, calcium chloride, glucose, Evans Blue, 
2, 3, 5 – triphenyltetrazolium chloride, sodium di-hydrogen phosphate, di-sodium 
hydrogen phosphate, 37% formaldehyde solution, potassium phosphate,  hydrochloric 
acid and ethyl acetate were obtained from Kimix Chemical and Laboratory supplies 
(South Africa). 
 
Tris, EDTA, ß- glycerolphosphate, tetra sodium pirophosphate, sodium orthovanadate, 
leupeptin, aprotinin, phenylmethyl sulphonyl fluoride, triton, Commassie Brilliant Blue, 
phosphoric acid, ethanol, sodium dodecyl sulphate, acrylamide, ammonium persulfate 
solution, Tetramethylethylenediamine, butanol, glycine, methanol, Ponseau stain and 
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antibodies were purchased from Cell Signaling Technology (Boston, United States of 
America). 
 
3.3 Animals 
  
All animals received humane care in accordance with the Principles of Laboratory 
Animal Care of the National Society of Medical Research and the Guide for Care and use 
of laboratory Animals of the National Academy of Sciences (National Institute of Health 
Publications no. 80 - 23, revised 1978). Male Wistar rats weighing between 220 – 250 g 
were used in preliminary experiments and rats weighing from 160 – 200 g were used for 
the chronic treatment with the plant extract. The animals were obtained from the 
University of Cape Town and the University of KwaZulu-Natal, South Africa. The 
animals were maintained in the Medical Biosciences Department animal house at 
University of the Western Cape and given free access to normal tap water and standard 
rat chow. The temperature of the animal room was maintained at 26 °C, with constant 
humidity and a 12-h light/dark cycle. The animals were kept in these conditions for a 
week to acclimatize to the new environment. 
 
3.4 Isolation of the rat heart 
The animals were anaesthetized by intraperitoneal injection (sodium pentabarbitone 40 
mg/kg). The diaphragm was accessed by a trans-abdominal incision to expose the 
thoracic cavity. The thorax was opened by bilateral incision along the lower margin of 
the last to the first rib to expose the heart. The heart was rapidly excised and immediately 
immersed in ice cold Krebs-Henseleit bicarbonate buffer solution containing (mM): 
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sodium chloride (119.00), sodium bicarbonate (25.00), potassium chloride (4.75), 
potassium di-hydrogen phosphate (1.2), magnesium sulphate (0.6), sodium sulphate (0.6), 
calcium chloride (1.25) and glucose 10, at pH 7.4.   
 
3.5 Preliminary experiments (Perfusion with O. africana extract) 
To determine whether treatment with O. africana aqueous extract is cardioprotective 
against ischemia-reperfusion injury, the working heart model according to Neely et al. 
(1967) was used. In all the preliminary experiments, the concentration of the extract used 
for the isolated heart was calculated based on the assumption that a 250 g rat has a blood 
volume of 16 ml (Diehl et al., 2001).  
 
3.5.1 Perfusion with different concentrations of O. africana extract  
 
Hearts were isolated as described in section 3.4 and perfused with Krebs-Henseleit buffer 
via the aortic cannula in a retrograde manner at 100 cm H2
 
O. After 10 min, the perfusion 
was switched to the working mode for 20 min. Hearts were then perfused for 10 min with 
one of the following concentrations of the extract: 10, 12, 20, 40 or 200 mg/kg rat. 
Parameters determined were coronary flow and aortic output using a measuring cylinder.  
3.5.2 Perfusion with O. africana extract at constant flow  
Hearts were perfused with O. africana extract (200 mg/kg) as described above except that 
the coronary flow was maintained at a constant rate (10.5 ml/min) using a peristaltic 
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pump. Parameters measured were aortic systolic and diastolic pressures using a pressure 
transducer connected to the data-acquisition system. 
 
3.5.3 Infusion with O. africana  
Hearts were also perfused with the infusion (200 mg/kg) prepared from O. africana 
powder from the leaves that were obtained in Parceval pharmaceutical company. The 
powder (50 mg) was dissolved in 16 ml of boiling water. The infusion was left overnight 
to allow it to steep and filtered before use. The perfusion protocol as described in section 
3.5.1 was followed. The parameter measured was coronary flow using a measuring 
cylinder. 
 
3.5.4 Light sensitivity of O. africana extract 
To determine whether the extract is light sensitive, hearts were perfused with the extract 
(1000 mg/kg) as described in section 3.5.1. The reservoir was covered with foil to protect 
the extract from the light. Parameters determined were coronary flow using a measuring 
cylinder and temperature using a thermal probe inserted into the coronary sinus. 
 
3.6 Chronic treatment of rats with O. africana extract 
To determine whether chronic treatment with the crude aqueous extract of Olea africana 
will protect the heart against ischemia-reperfusion injury, rats were subjected to one of 
the following protocols.   
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3.6.1 Effect of chronic treatment with O. africana extract on cardiac 
function 
 
For the evaluation of cardiac function, 16 rats were used. They were divided into the 
control group (n=8) and the O. africana group (n=8).  The control group received normal 
tap water. The O. africana group received the extract of O. africana in the drinking water 
(1000 mg/kg). The average volume of water consumed by the animals per cage and the 
body weights were recorded twice a week to determine the correct quantity of the extract 
to be used. Rats were treated for 5 weeks. 
 
The Langendorff isolated perfused heart as described by Langendorff (1895) was used as 
our experimental model. After removal, the hearts were perfused via the aortic cannula in 
a retrograde manner at 100 cm H2O with Krebs-Henseilet buffer oxygenated with 95% 
O2 / 5% CO2 at 37 °C. During the initial perfusion, excess tissue from the heart was 
removed. A latex balloon filled with normal saline was inserted into the left ventricle via 
the left atrium. The balloon was connected to a pressure transducer which was connected 
to a data-acquisition system to record cardiac function. Left ventricular end-diastolic 
pressure was set between 4 - 10 mmHg. The temperature of the heart was monitored by a 
thermal probe inserted in the coronary sinus and was maintained at 37 °C. After 30 min 
perfusion, global ischemia was induced for 20 min by occluding the perfusion inflow 
lines to the aorta. During ischemia the temperature of the heart was maintained at 36.6 
°C. After 20 min ischemia, reperfusion was initiated by opening the inflow lines to the 
aorta. At the end of 30 min reperfusion, hearts were freeze-clamped with Wollenberger 
clamps pre-cooled in liquid nitrogen. The hearts were then kept at –80 °C for PKB / Akt 
determination. PKB / Akt were determined as described in section 3.6.3.1. 
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3.6.1.1 Parameters measured  
A pressure transducer connected to the balloon was connected to a data-acquisition 
system to record the left ventricular systolic and diastolic pressures and heart rate. A 
measuring cylinder was used to collect and measure coronary flow. The readings were 
taken at the end of stabilization and reperfusion periods. Cardiac function was determined 
by left ventricular developed pressure (LVDevP) and rate pressure product (RPP). Left 
ventricular developed pressure is equal to systolic pressure minus diastolic pressure. Rate 
pressure product is equal to heart rate multiplied by left ventricular developed pressure. 
Functional recovery was expressed as percentage of the pre-ischemic value using the 
following formulae: 
 
% RPP recovery = (RPP post-ischemic/RPP pre-ischemic) ×100 
% LVDevP recovery = (LVDevP post- ischemic/LVDevP pre-ischemic) × 100 
 
3.6.2 Effect of chronic treatment with O. africana extract on cardiac 
infarct size 
          
For the determination of infarct size, 24 rats were used. They were divided into the 
control group (n=5), O. africana group (n=6), captopril group (n=5) and the jelly 
(vehicle) group (n=6). The first (control) group received normal tap water. The second 
(O. africana) group received the extract of O. africana in the drinking water (1000 
mg/kg/day). The average volume of water consumed by the animals per cage and the 
body weights were recorded twice a week to determine the correct quantity of the extract. 
The third (captopril) group received captopril (50 mg/kg/day) in jelly blocks. The fourth 
 
 
 
 
 33 
(jelly) group received jelly blocks daily as a vehicle control for captopril. All rats 
received normal laboratory rat chow. Rats were treated for 5 weeks. 
  
At the end of treatment period, hearts were isolated and perfused according to the method 
described in section 3.6.1. After 30 min perfusion, regional ischemia was induced for 45 
min by left coronary artery ligation using a silk suture. During regional ischemia, the 
temperature of the heart was maintained at 36.6 °C. Reperfusion was initiated for 35 min 
by loosening the suture. At the end of the experiment, the suture around the left coronary 
artery was securely tied and ± 500 µl of 0.2% Evans Blue suspension was slowly injected 
via the aortic cannula. The hearts were removed and frozen at -20 °C for 24 - 48 hours 
before analysis.  After freezing, the heart was cut into 2-mm thick slices and stained in 
the dark with 1% w/v triphenyltetrazolium chloride in phosphate buffer (pH 7.4) at 37 °C 
for 15 - 20 min. Slices were then fixed in 10% v/v formaldehyde solution to enhance the 
contrast between stained viable tissue and unstained necrotic tissue. The area at risk and 
the area of infarcted tissue in the risk zone were determined using The University of 
Texas Health Science Center at San Antonio (UTHSCSA) Image tool software version 3. 
The infarct size was expressed as a percentage of the risk zone. 
 
3.6.3 Effect of chronic treatment with O. africana extract, captopril and 
jelly on PKB / Akt  
 
For PKB / Akt analysis 20 rats were used. They were divided and treated according to the 
groups described in section 3.6.2. Each group comprised of 5 animals. 
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3.6.3.1 Protein determination 
At the end of treatment period, animals were sacrificed and prepared according to the 
method described in 3.4. The hearts were then kept at -80 °C. The tissue from the left 
ventricle was homogenized for 8 sec in a lysis buffer containing: Tris 20 mM, EDTA 
1mM, sodium chloride 150 mM, ß-glycerolphosphate 1mM, tetra sodium pirophosphate 
2.5 mM, sodium orthovanadate 1mM, leupeptin 10 µg/ml, aprotinin 10 µg/ml, 
phenylmethyl sulphonyl fluoride 50 µg/ml and triton 1% and then centrifuged at 14500 
rpm for 10 min. The supernatant was drawn and the lysate protein content was 
determined using the Bradford assay (Bradford, 1976). After protein determination, 
lysates were diluted in Laemmli sample buffer, boiled for 5 min and stored at –20 °C for 
western blot analysis. Lysates were boiled for 5 min and the protein (25 ug/ul) was 
separated on a 12% Sodium dodecyl sulphate gel. The separated proteins were transferred 
to the PVDF membrane (Immobilon TM P, Millipore) and the membrane was stained with 
Ponceau red for visualization of the protein.  The membrane was then washed 3 times 
with 10 X TBS Tween (TBST) and non-specific binding sites were blocked by 5% fat 
free milk in TBST. The membrane was then washed 6 times with TBST and incubated 
with the primary antibody that recognizes phosphospecific PKB (Ser 473 and Thr 308). The 
membrane was then washed 6 times with TBST for 5 min before incubated with the 
secondary antibody. After washing with TBST, the membrane was covered with ECL TM 
detecting reagents for 1 min and quickly exposed to an autoradiography film (Hyperfilm 
ECL, RPN 2103) to detect light emission (ECL TM 
 
Western Blotting). Films were 
densitometrically analyzed (UN-SCAN-IT, silkscience).  
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3.7 Statistical analysis 
Results are expressed as the mean ± SEM (standard error of the mean). Two groups were 
compared using either the Mann-Whitney or t test, when appropriate. Multiple groups 
were compared using either Kruskal-Wallis or One-way ANOVA test, when appropriate. 
A p-value < 0.05 was considered statistically significant. Tests were performed using 
SPPS V16.0 statistical package (http://www.spss.com) and graphs were plotted using 
Graph Pad Prism version 5.02 (http://www.graphpad.com). 
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CHAPTER 4 
 
RESULTS 
 
 
4.0 Percentage yield of the extract 
 
From the leaves that were harvested at the University of the Western Cape, 1039.14 g of 
the ground powder was used and 79.98 g of the lyophilysate was obtained, thus 
producing a 8% yield. Of the ground powder obtained from Parceval pharmaceutical 
company, 2400 g was used and the powder obtained after freeze drying was 326.45 g, 
thus producing a 13.6% yield.  
 
4.1 The brine shrimp toxicity test 
The toxicity of the plant extract was determined using nine concentrations of O. africana 
crude aqueous extract (Table 4.1). The LC50
 
 was 1269 mg/ml and the associated 95% 
confidence interval was 1016 to 1586 mg/ml (Appendix Ι). At a concentration of 2250 
mg/ml all shrimps were killed. 
Table 4.1 The percentage lethality of the different concentration of O. africana 
extract on brine shrimps 
 
Concentration (mg/ml) 
2.5     10     25     50     250     750     1250     1750     2250 
Control            0        0       0      0       0         0          0           0          0 
 
O. africana      0       0        0      8       18       25        40         68         100 
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Figure 4.1 Toxicity of the aqueous extract of O. africana. The stippled line show the 
non-linear regression 
 
 
4.2 Preliminary experiments 
 
In all the experiments in which rat hearts were perfused with the plant extract, no 
statistics are presented due to the small sample size used. The reason for the small sample 
size is because the coronary flow decreased dramatically, we therefore, switched to a 
model where the animals were treated with the plant extract. 
 
4.2.1 Perfusion with different concentrations of O. africana extract  
 
To determine a suitable concentration of the extract to be used, rat hearts were perfused 
with Krebs-Henseleit buffer for 10 min in the Langendorff mode, followed by 20 min 
perfusion in the working mode. Hearts were then perfused with different concentrations 
of O. africana extract in the Langendorff mode for 10 min. The coronary flow and aortic 
output of hearts perfused with the Krebs-Henseleit buffer was not different between 
 
 
 
 
 38 
groups, averaging from 16.6±1.8 ml/min to 17.5±0.8 ml/min and between 35.0±1.1 
ml/min and 40.2±4.3 ml/min respectively (Table 4.2). When hearts were perfused with 
the extract, coronary flow averaged from 0.3±0.0 ml/min to 0.6±0.1 ml/min and aortic 
output could not be measured. When hearts were perfused with the extract, coronary flow 
(Table 4.2), decreased significantly at all concentrations.  
             
Table 4.2 Effect of perfusion with different concentrations of O. africana extract on 
cardiac function 
              
Number     Working heart Perfusion          Langendorff Perfusion 
of hearts    CF                  AO                        Extract  conc    CF                AO  
                   (ml/min)        (ml/min)                (mg/kg)             (ml/min)      (ml/min)                   
   
                                                        
 
            
2                 17.5±0.8         40.2±4.3                 10                     0.6±0.1         ND    
2                 17.3±1.3         36.4±2.0                 12                     0.3±0.4         ND 
2                 17.3 ±1.1        38.1±1.7                 20                     0.4±0.0         ND 
3                 15.6±0.6         35.0±1.1                 40                     0.3±0.1         ND 
4                 16.6±1.8         35.0 ±3.0                200                   0.3±0.0         ND 
Results are expressed as the mean±SEM, ND= not detectable (Langendorff mode) 
                        
 
4.2.2 Perfusion with O. africana extract at constant flow 
                         
To determine the effect of the plant extract on cardiac function when perfused at constant 
flow, hearts were perfused with Krebs-Henseleit buffer for 10 min in the Langendorff 
mode, followed by 20 min perfusion in the working mode. Hearts were then perfused 
with O. africana (200 mg/kg) extract in the Langendorff mode for 10 min with coronary 
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flow set at 10.5 ml/min using a peristaltic pump. During perfusion with the Krebs-
Henseleit buffer, systolic aortic pressure was 90.1±0.3 mmHg and diastolic aortic 
pressure was 40.0±1.1 mmHg. When hearts were perfused with the extract, the 
contraction of the heart became weaker until, after 4 - 7 min, the heart stopped beating. 
Coronary flow decreased from 10.5 ml/min to 0.3±0.1 ml/min, despite the peristaltic 
pump being used.  
                              
Table 4.3 Effect of perfusion with O. africana extract at constant flow  
 
                                                   Systolic aortic pressure      Diastolic aortic pressure 
                                                             (mmHg)                             (mmHg)                                                                                                              
Perfusion with Krebs-Henseleit      90.1±0.3                                    40.0±1.1         
Bicarbonate buffer 
 
Perfusion with O. africana              ND                                              ND                       
 
Results are expressed as the mean±SEM, n=3; ND= not detectable 
 
4.2.3 Effect of O. africana infusion  
To determine the effect of O. africana infusion on cardiac function, hearts were perfused 
with Krebs-Henseleit buffer for 10 min in the Langendorff mode, followed by 20 min 
perfusion in the working mode. Hearts were then perfused with the infusion of O. 
africana (200 mg/kg) in the Langendorff mode for 10 min. When hearts were perfused 
with the infusion of O. africana, coronary flow decreased from 16.1±0.4 ml/min to 
0.5±0.3 ml/min (Table 4.4).                                                 
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Table 4.4 Effect of O. africana infusion on coronary flow   
                     
                                                           Coronary Flow  
                                                                        (ml/min)                              
Perfusion with Krebs-Henseleit                        16.1±0.4                                                    
Bicarbonate buffer 
 
Perfusion with O. africana                                0.5±0.3                                                   
 
Results are expressed as the mean±SEM, n=2 
 
4.2.4 Light sensitivity of O. africana extract 
To determine whether the effect of O. africana extract described above was due to light 
sensitivity, the reservoir was covered with foil to protect the extract from light. Hearts 
were perfused with Krebs-Henseleit buffer for 10 min followed by 10 min perfusion with 
O. africana extract. When hearts were perfused with Krebs-Henseleit bicarbonate buffer, 
coronary flow was 9.6±0.4 ml/min and decreased to 0.4±0.0 ml/min during perfusion 
with O. africana extract. Temperature also decreased from 35.6±0.0 °C during perfusion 
with the Krebs-Henseilet buffer to 31.2±0.7 °C when hearts were perfused with the plant 
extract (Table 4.5). 
 
Table 4.5 Effect of perfusion with O. africana extract on coronary flow and 
temperature 
 
                                              Coronary Flow                             Temp  
                                                         (ml/min)                                     (°C)                                          
                                                           
Perfusion with Krebs-Henseleit            9.6±0.4                                    35.6±0.0 
Bicarbonate buffer 
 
Perfusion with O. africana                      0.4±0.0                                 31.2±0.7 
 
Results are expressed as the mean±SEM, n=4 
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4.3 Effects of chronic treatment with O. africana extract on cardiac 
function 
 
After the rats were treated with O. africana extract for 5 weeks, hearts were isolated and 
perfused with Krebs–Henseilet bicarbonate buffer for 30 min in the Langendorff mode, 
followed by 20 min global ischemia. Hearts were then reperfused for 30 min in the 
Langendorff mode. 
 
4.3.1 Coronary flow 
 
Coronary flow was similar before and after ischemia in the control (11.4±0.9 versus 
10.1±1.0 ml/min, p>0.05) and O. africana (10.6±0.8 versus 10.1±0.6 ml/min, p>0.05) 
groups. There was no significance difference between the control and O. africana groups 
before ischemia (11.4±0.9 ml/min versus 10.6±0.8 ml/min) and after ischemia (10.1±1.0 
ml/min versus 10.1±0.6 ml/min, p>0.05) (Figure 4.2). 
 
                    
 
Figure 4.2 Effect of chronic treatment with O. africana extract on coronary flow. 
Values are expressed as the mean±SEM; n=8 in each group           
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4.3.2 Systolic ventricular pressure 
 
In the control group, systolic ventricular pressure before ischemia was 94.9±3.4 mmHg 
and 105.1±5.1 mmHg after ischemia, p>0.05. In the O. africana group, systolic 
ventricular pressure before ischemia was 90.5±1.9 mmHg and 89.3±4.1 mmHg after 
ischemia, p>0.05. Systolic ventricular pressure was similar in O. africana and the control 
groups before ischemia (90.5±1.9 versus 94.9±3.4 mmHg), p>0.05. After ischemia, 
systolic ventricular pressure differed significantly between the groups (89.3±4.1 versus 
105.1±5.1 mmHg), p<0.05, (Figure 4.3). 
 
Figure 4.3 Effect of chronic treatment with O. africana extract on systolic                                   
ventricular pressure. Values are expressed as the mean±SEM; n=8 in each group, 
*p<0.05 compared to the Post-ischemic control group 
                                                                    
 
4.3.3 Diastolic Ventricular Pressure 
 
The diastolic pressure in the control group before ischemia was 10.3±0.3 mmHg and 
increased to 32.5±5.3 mmHg after ischemia, p<0.05. Diastolic ventricular pressure in the 
O. africana group before ischemia was 10.0±0.4 mmHg and increased to 21.4±2.5 
mmHg after ischemia, p<0.05. There was no significance difference between the control 
* 
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and O. africana groups before (10.3±0.3 versus 10.0±0.4 mmHg) and after ischemia 
(32.5±5.3 versus 21.4±2.5 mmHg), p>0.05 (Figure 4.4). 
 
Figure 4.4 Effect of chronic treatment with O. africana extract on diastolic                                       
ventricular pressure. Values are expressed as the mean±SEM; n=8 in each group,                         
*p <0.05 compared to before ischemia in the same group 
                       
 
4.3.4 Heart rate 
 
The heart rate in the control group was similar before and after ischemia (289.3±11.7 
versus 267.3±12.8 bpm), p>0.05. Heart rate in the O. africana group before ischemia was 
312.5±12.1 bpm and decreased to 292.0±6.8 bpm after ischemia, p<0.05. When 
comparing the groups, heart rate was similar before ischemia (289.3±11.7 versus 
312.5±12.1 bpm, control vs O. africana) and after ischemia (267.3±12.8 versus 
292.0±6.8 bpm, control vs O. africana), p>0.05 (Figure 4.5). 
          
 
   * 
* 
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Figure 4.5 Effect of chronic treatment with O. africana extract on heart rate. Values 
are expressed as the mean±SEM; n=8 in each group, *p<0.05 compared before ischemia 
in the same group 
 
 
4.3.5 Left ventricular developed pressure (LVDevP) 
 
The LVDevP in the control group before ischemia was 84.6±3.4 mmHg and decreased to 
72.6±5.2 mmHg after ischemia, p<0.05. In the O. africana group, LVDevP before 
ischemia was 80.5±2.0 mmHg and decreased to 67.9±4.3 mmHg after ischemia, p<0.05. 
There was no significance difference in LVDevP between O. africana and control groups 
before (80.5±2.0 versus 84.6±3.4 mmHg respectively) and after ischemia (67.9±4.3 
versus 72.6±5.2 mmHg respectively), p>0.05 (Figure 4.6). 
 
 
 
 
 
 
 
 
 
 
 
                         
* 
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Figure 4.6 Effect of chronic treatment with O. africana extract on left ventricular                                     
developed pressure. Values are expressed as the mean±SEM; n=8 in each group,              
*p <0.05 compared to before ischemia in the same group 
                
 
4.3.6 Rate pressure product (RPP) 
The RPP in the control group before ischemia was 24346.8±938.1 mmHg/min and 
decreased to 19367.5±1581.1 mmHg/min after ischemia, p<0.05. In the O. africana 
group, the rate pressure product before ischemia was 25129.5±1077.7 mmHg/min and 
decreased to 19893.3±1504.6 mmHg/min after ischemia, p<0.05. Rate pressure product 
was similar before ischemia in the control group (24346.8±938.1 mmHg/min) and O. 
africana group (25129.5±1077.7 mmHg/min, p>0.05). There was no significance 
difference after ischemia between the control group (19367.5±1581.1 mmHg/min) and 
the O. africana group (19893.3±1504.6 mmHg/min, p>0.05) (Figure 4.7).    
 
 
     * 
   * 
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Figure 4.7 Effect of chronic treatment with O. africana extract on rate pressure                                          
product. Values are expressed as the mean±SEM; n=8 in each group, *p <0.05 compared 
to before ischemia in the corresponding group 
 
 
4.3.7 Recovery of the left ventricular developed pressure  
The percentage recovery of the LVDevP was similar in the control group (85.6±4.6 %) 
and the O. africana group (84.4±5.1 %) p>0.05 (Figure 4.8).    
 
Figure 4.8 Effect of chronic treatment with O. africana extract on percentage                                    
recovery of the left ventricular developed pressure. Values are expressed as the 
mean±SEM; n=8 in each group   
 
* 
 * 
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4.3.8 Recovery of rate pressure product  
 
There was no significance difference in the rate pressure product recovery between the 
control group (79.4±5.1 %) and the O. africana group (79.3±5.7 %), p>0.05 (Figure 4.9).    
 
 
Figure 4.9 Effect of chronic treatment with O. africana extract on percentage                                
recovery of rate pressure product. Values are expressed as the mean±SEM; n=8 in 
each group   
                         
 
4.4 The effect of ischemia-reperfusion injury on total PKB / Akt  
 
 Figure 4.10A shows the Western blot of total PKB / Akt of the control and O. africana 
groups. The total PKB / Akt was similar in the O. africana (1.0±0.1) and the control 
group (1.0±0.0), p>0.05 (Figure 4.10B). The values are expressed relative to the control 
(control =1). 
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                   Control                                    Olea africana 
 
 
 
Figure 4.10A Western blot of total PKB / Akt in hearts subjected to ischemia-    
reperfusion injury.  
               
 
                          
Figure 4.10.B The effect of ischemia-reperfusion on total PKB / Akt. Values are 
expressed as the mean±SEM; control n=6, O. africana n=7  
 
 
4.4.1 The effect of ischemia-reperfusion injury on PKB / Akt             
phosphorylation 
                             
              
Figure 4.11A shows the Western blot of phosphorylated PKB / Akt of the control and O. 
africana groups. The PKB / Akt phosphorylation was similar in the O. africana (1.1±0.2) 
and the control groups (1.0±0.0), p>0.05, (Figure 4.11B). Values are expressed relative to 
the control (control=1). 
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                    Control                               Olea africana    
 
 
Figure 4.11A Western blot of PKB / Akt phosphorylation in hearts subjected  
to ischemia-reperfusion. 
 
 
                           
Figure 4.11B The effect of ischemia-reperfusion on PKB / Akt                                      
phosphorylation. Values are expressed as the mean±SEM; control n=6, O. africana n=7  
                    
            
4.5 Chronic treatment with O. africana extract, captopril and jelly on 
cardiac function and infarct size  
 
4.5.1 Coronary flow 
The average coronary flow before ischemia was 11.7±0.9 ml/min in the control group, 
11.6±0.7 ml/min in the Olea africana group, 11.4±0.8 ml/min in the captopril group and 
11.8±0.5 ml/min in the jelly group, p>0.05. During ischemia the average coronary flow 
decreased in the control (6.3±0.6 ml/min), O. africana (6.1±0.5 ml/min), captopril 
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(5.9±0.5 ml/min) and jelly groups (6.4±0.3 ml/min), p<0.05. In all the groups, the 
average coronary flow during ischemia decrease to 53%. 
 
4.5.2 Left ventricular developed pressure (LVDevP) 
The LVDevP was similar before ischemia in the control group (106.8±4.8 mmHg), O. 
africana group (109.7±3.7 mmHg), captopril group (96.6±2.6 mmHg) and the jelly group 
(105.0±2.8 mmHg), p>0.05. The LVDevP in the control group before ischemia was 
106±4.8 mmHg and decreased during ischemia to 70.4±2.4 mmHg, and after ischemia to 
59.8±2.6 mmHg, p<0.05. The LVDevP in the O. africana group during and after 
ischemia (64.4±3.1 mmHg and 64.0±1.9 mmHg respectively) differed significantly 
(p<0.05) from the pre-ischemic value (109.7±3.7 mmHg).  There was a significant 
difference in LVDevP in the captopril group before, during and after ischemia (96.6±2.6 
mmHg, 66.4±3.1 mmHg and 67.0±3.6 mmHg respectively), p<0.05. The LVDevP 
differed significantly in the jelly group before ischemia (105±2.8 mmHg), during 
ischemia (79.5±2.4 mmHg) and after ischemia (68.5±2.3 mmHg), p<0.05. During 
ischemia, LVDevP in the control group was 70.4±2.4 mmHg, in the O. africana group 
64.0±2.5 mmHg, in the captopril group 66.4±3.1 mmHg and in the jelly group 79.5±4.2 
mmHg, p>0.05. There was no significant difference after ischemia in the control group 
(59.8±2.6 mmHg), the O. africana group (64.0± 1.9 mmHg), the captopril group 
(67.0±3.6 mmHg) and the jelly group (68.5±2.3 mmHg), p>0.05, (Figure 4.12).    
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Figure 4.12 Effect of chronic treatment with O. africana extract, captopril and jelly 
on left ventricular developed pressure. Values are expressed as the mean±SEM; 
control group n=5, O. africana n=6, captopril n=5, jelly (vehicle, n=6), *p<0.05 
compared to pre-ischemia, ▪p<0.05 (post-ischemia compared to ischemia). 
 
4.5.3 Rate pressure product (RPP) 
The RPP was similar before ischemia in the control group (40912.4±1801.1 mmHg/min), 
O. africana group (35787.2±1397.0 mmHg/min), captopril group (35934.2±1380.4 
mmHg/min) and jelly group (34942.2±1316.2 mmHg/min) p>0.05. The RPP in the 
control group before ischemia was 40912.4±1801.1 mmHg and decreased during 
ischemia to 30626±2126.8 mmHg, and after ischemia to 24142±1187.7 mmHg, p<0.05. 
The RPP in the O. africana group during and after ischemia (20214.7±1302.4 mmHg and 
20083.7±676.1 mmHg, respectively) differed significantly (p<0.05) from the pre-
ischemic value (35787.2±137 mmHg). There was a significance difference in RPP in the 
captopril group before, during and after ischemia (35934.2±1380.4 mmHg, 23749±1221 
mmHg and 23172.8±547.8 mmHg, respectively, p<0.05). The RPP differed significantly 
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in the jelly group before ischemia (34942.2±1316.2 mmHg), during ischemia 
(26546.2.5±957.7 mmHg) and after ischemia (21691.3±1283.2 mmHg, p<0.05). After 
ischemia, the RPP was similar in the control group (24142.0±1187.7 mmHg/min), O. 
africana group (20083.7±676.1 mmHg/min), captopril group (23172.8±547.8 
mmHg/min) and the jelly group (21691.3±1283.2 mmHg/min) p>0.05. RPP during 
ischemia was lower in the O. africana group (20214.2±1302.4 mmHg/min) and captopril 
group (23749.0±1221.2 mmHg) compared to the control group (30626.2±2126.8 
mmHg/min), p<0.05 (Figure 4.13).  
  *  
Figure 4.13 Effect of chronic treatment with O. africana extract, captopril and jelly 
on rate pressure product. Values are expressed as the mean±SEM; Control group n=5, 
O. africana n=6, captopril n=5, jelly (vehicle, n=6), *p<0.05 compared to pre-ischemia,  
▪p<0.05 (post-ischemia compared to ischemia) 
 
4.5.4 Recovery of the left ventricular developed pressure  
There was no significance difference in percentage recovery of the left ventricular 
developed pressure between the O. africana (58.8±3.2 %), jelly (65.3±0.8 %) and the 
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control groups (56.2±3.0 %,), p>0.05. Percentage recovery of the left ventricular 
developed pressure differed significantly in the captopril group (69.4±3.0 %) compared 
to the control group (56.2±3.0 %, p<0.05) (Figure 4.14).    
 
Figure 4.14 Effect of chronic treatment with O. africana extract, captopril and jelly 
on percentage recovery of left ventricular developed pressure. Values are expressed 
as the mean±SEM; control group n=5, O. africana n=6, captopril n=5, jelly (vehicle, 
n=6), *p<0.05 compared to control group  
 
4.5.5 Recovery of rate pressure product (RPP) 
The percentage recovery of the rate pressure product was the same in the O. africana 
(56.8±3.7 %), captopril (64.6±1.2 %), jelly (62.2±1.7 %) and the control groups 
(59.2±2.3 %), p>0.05 (Figure 4.15). 
  
* 
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 Figure 4.15 Effect of chronic treatment with O. africana extract, captopril and jelly 
on percentage recovery of rate pressure product. Values are expressed as mean±SEM; 
control group n=5, O. africana n=6, captopril n=5, jelly (vehicle, n=6)   
 
       
4.5.6 Infarct size 
The infarct size (expressed as a % of the area at risk) was the same in O. africana 
(41.3±3.5 %), captopril (41.0±3.8 %), jelly (42.5±4.1 %) and the control groups 
(40.6±3.2 %), p>0.005, (Figure 4.15). There was no significance difference in the 
percentage of the area at risk in O. africana (54.2±5.4 %), captopril (51.8±4.0 %), jelly 
(47.2±2.2 %) and control groups (48.4±3.5 %), p>0.005, (Figure 4.16).   
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Figure 4.16 Effect of chronic treatment with O. africana extract, captopril and jelly 
on infarct size of perfused hearts. Values are expressed as the mean±SEM; control 
group n=5, O. africana n=6, captopril n=5, jelly (vehicle, n=6)   
 
 
 
 
Figure 4.17 Effect of chronic treatment with O. africana extract, captopril and jelly 
on area at risk. Values are expressed as the mean±SEM; control group n=5, O. africana 
n=6, captopril n=5, jelly (vehicle, n=6)   
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4.6 Chronic administration of O. africana extract, captopril and jelly on 
total PKB/Akt                     
        
Figure 4.18A shows the Western blot of total PKB / Akt of the control, O. africana, 
captopril and jelly groups. The total PKB / Akt was similar in O. africana (0.7±0.1), 
captopril (0.7±0.1), jelly (0.7±0.1) compared to the control group (1.0±0.0), p>0.05, 
(Figure 4.18B). The values are expressed relative to the control (control=1). 
 
 
 
 
             Figure 4.18A Western blot of total PKB / Akt expression in non perfused        
                                     hearts  
  
 
 
 
 
 
    Control   O. africana   Captopril        Jelly   
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Figure 4.18B The effect of chronic administration of O. africana extract, captopril 
and   jelly on total PKB / Akt. Values are expressed as the mean±SEM; control group 
n=2, O. africana n=4, captopril n=4, jelly (vehicle, n= 4)   
  
                        
                     
4.6.1 Effect of chronic administration of O. africana, captopril and jelly  
on PKB/Akt phosphorylation                        
Figure 4.19A shows the Western blot of phosphorylated PKB / Akt of the control, O. 
africana, captopril and jelly groups. Phosphorylated PKB / Akt was similar in the O. 
africana group (3.1±0.4), captopril (3.1±0.5), jelly (4.2±0.8) and the control groups 
(1.3±0.0), p>0.05, (Figure 4.19B).  
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Figure 4.19A Western blot of PKB/Akt phosphorylation in non perfused hearts 
 
 
 
Figure 4.19B Effect of chronic administration of O. africana, captopril and jelly                        
on PKB/Akt phosphorylation. Values are expressed as the mean±SEM; control group 
n=2, O. africana n=4, captopril n=4, jelly (vehicle, n= 4) 
 
 
 
 
 
 
      Control    O. africana  Captopril        Jelly 
* 
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CHAPTER 5 
DISCUSSION 
 
5.1 Toxicity of O. africana extract 
A concentration of 2250 mg/ml killed all (100%) the brine shrimps. The concentrations 
used for the preliminary experiments or acute treatment (2.5 mg/ml to 50 mg/ml) and 
chronic treatment experiments (1000 mg/kg or 250 mg/ml) are not toxic to the rats 
(LC50=1269 
 
mg/ml) (Table 4.1; Figure 4.1).  
5.2 Acute treatment with O. africana extract 
The initial objective was to determine the effects of O. africana extract on ischemia-
reperfusion injury on the isolated perfused rat heart. Initially, hearts were perfused at 
constant hydrostatic pressure (100 mmHg) with different concentrations of the O. 
africana extract to determine the suitable concentration of the plant extract. In all the 
different concentrations of the plant extract used, cardiac function decreased as evidenced 
by a significant decrease in coronary flow (Table 4.2). The heart rate and force of 
contraction also decreased (not shown in the results). The findings suggest that the plant 
extract might contain toxic effects, however, our results from the brine shrimp toxicity 
test indicate that the concentrations that were used to perfuse the heart are not toxic 
(Table 4.1; Figure 4.1). The effects of the plant extract suggest that the extract has 
vasoconstritory properties on the coronary arteries.  
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Due to the observed effects above of the plant extract, hearts were then perfused with the 
plant extract (200 mg/kg) at constant flow rate (10.5 ml/min) to force the extract through 
the heart to determine whether the extract will have the same observed effects. Cardiac 
function again decreased until the heart stopped beating (Table 4.3). It was also observed 
that after 4 - 7 min of perfusion with the plant extract, coronary flow decreased 
completely despite the peristaltic pump being used. We then perfused the hearts with an 
infusion (200 mg/kg) of the plant extract to determine whether there is any difference due 
to the extraction methods used. The same effects were observed when the plant extract 
was used, i.e., coronary flow decreased significantly, p< 0.05 (Table 4.4). Hearts were 
then perfused with the plant extract (200 mg/kg), covering the reservoir containing the 
plant extract to determine whether the effects observed with the plant extract were due to 
the light sensitivity of the plant extract. Cardiac function again decreased significantly 
(Table 4.5). In the isolated perfused heart, perfusion with Olea europaea ethanol leaf 
extract decreased systolic left ventricular pressure and heart rate, but  increased relative 
coronary flow (ratio between coronary flow and rate pressure product) (Scheffler et al., 
2008). The findings of these authors disagree with our results and this might be due to the 
different extracts (aqueous versus ethanol) and the species (Olea europaea versus Olea 
africana) used.  
 
5.3 Effect of chronic treatment with O. africana extract  
 
Due to the fact that we could not perfuse the heart with the plant extract, we then treated 
the rats with the O. africana extract daily for 5 weeks.  
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5.3.1 Effect of chronic treatment with O. africana extract on cardiac 
function 
 
Chronic treatment with O. africana aqueous extract (1000 mg/kg/day) had no effect on 
cardiac function of the isolated heart in terms of coronary flow, left ventricular systolic 
pressure, left ventricular diastolic pressure, heart rate, left ventricular developed pressure 
and rate pressure product compared to the control group. In this study, we showed that 20 
min ischemia decreased cardiac function during reperfusion as evidenced by an increase 
in left ventricular diastolic pressure, a decreased in left ventricular developed pressure 
and rate pressure product. These findings are in agreement with studies that have shown 
that ischemia decrease cardiac function (Apstein et al., 1977; Takeda et al., 1997, Narang 
et al., 2004). The increase in end-diastolic pressure reflects diastolic dysfunction and is a 
representative of the left ventricle’s inability to relax during diastole (Venardos et al., 
2004). Olea africana treatment did not affect post-ischemic coronary flow (Figure 4.2),  
left ventricular diastolic pressure (Figure 4.4), left ventricular developed pressure (Figure 
4.6), rate pressure product (Figure 4.7), percentage recovery of the left ventricular 
developed pressure (Figure 4.8) and percentage recovery of  the rate pressure product 
(Figure 4.9) compared to the control group. Although it appears that the post-ischemia 
left ventricular systolic pressure (Figure 4.3) and heart rate (Figure 4.5) decreased in the 
O. africana treated group, it was not significant. These results demonstrate that chronic 
treatment with the crude aqueous extract of O. africana leaves did not offer 
cardioprotection against ischemia-reperfusion injury as evidenced by lack of 
improvement in functional recovery (% LVDP and % RPP). 
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5.3.2 Effect of ischemia-reperfusion injury on PKB / Akt 
 
In this study, we hypothesized that ACE inhibitors, by decreasing AII levels, increase PI-
3-kinase activity and thus activates PKB (for motivation refer to page 2-3). In response to 
ischemia, cells activate various signal transduction pathways which may either be 
harmful to the organism or allow it to adapt to the stressful environment (Engelbrecht et 
al., 2006). Ischemia followed by reperfusion has been shown to activate the pro-survival 
Akt, p42/p44 and Erk 1/2 kinases, which are termed reperfusion injury salvage kinase 
(RISK) pathways. The RISK pathways has been implicated in cellular survival through 
the recruitment of anti-apoptotic mechanism by phosphorylating the pro-apoptotic protein 
BAD. Phosphorylation of BAD by p42/p44, Erk 1/2 or PKB results in its binding to 14-3-
3 proteins, which prevent it from binding to its mitochondrial target, thereby preventing 
apoptosis (Lawlor et al., 2001; Hausenloy et al., 2004). Activation of the RISK pathways 
also inhibits the conformational change in BAX (pro-apoptotic protein) required for its 
translocation to the mitochondria, thereby preventing apoptosis (Hausenloy et al., 2004). 
We therefore investigated the involvement of the PKB / Akt protein in the cellular 
response to treatment with O. africana crude aqueous extract. We have chosen to 
investigate PKB / Akt involvement because, to our knowledge, there is no study showing 
a link between ACE inhibitors and PKB activity in ischemia-reperfusion injury. The 
results demonstrated that there was no change in total PKB /Akt, which showed that PKB 
expression was the same in all groups. Chronic treatment with O. africana extract had no 
effect on PKB / Akt, phosphorylation compared to the control group, p>0.05 (Figure 
4.11B). In another set of experiments (discussed later), PKB activity was increased 3 fold 
in hearts isolated from O. africana treated rats. In this set of experiments, however, 
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animals were treated with O. africana crude aqueous extract and hearts were then isolated 
and perfused with Krebs-Henseleit buffer before being subjected to an ischemic-
reperfusion protocol. PKB / Akt activity was measured at the end of the reperfusion 
period. Perfusing the hearts with Krebs-Henseleit buffer prior to ischemia, and in the 
absence of O. africana, could have resulted in the loss of PKB activity  
 
5.4. Effect of chronic treatment with O. africana extract, captopril and 
jelly on infarct size  
 
ACE inhibitors have been shown to protect against ischemia-reperfusion injury (Ozer et 
al., 2002; Eichhorn, 1998; Maulik et al., 2001; Takeda et al., 1997). The aqueous extract 
from the leaves of O. africana have angiotensin converting enzyme (ACE) inhibitory 
effects (Adersen et al., 1997; Hansen et al., 1996) and we therefore assumed that O. 
africana by virtue of its ACE inhibitory effects will protect against ischemia-reperfusion 
injury. In our system, chronic treatment with the O. africana extract did not protect 
against ischemia-reperfusion. We therefore treated rats with captopril (an angiotensin 
converting enzyme inhibitor) as a positive control to determine whether it protects against 
ischemia-reperfusion injury in our experiments. Our results showed that chronic 
treatment with O. africana crude aqueous extract and captopril did not limit infarct size 
(Figure 4.16). These findings are not in agreement with pervious results by Ozer et al. 
(2002) who showed that acute administration of captopril (3 mg/kg) in an in vivo model 
of myocardial ischemia-reperfusion injury decreases infarct size. Similarly, Maulik et al. 
(2001) using the same model showed that captopril (4 mg/kg) improves post-ischemia 
cardiac function. Treatment with captopril (8 µg/ml or 80 µg/ml) before ischemia 
provided protection in isolated perfused hearts (Takeda et al., 1997). The reason for the 
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different findings may be due to the different protocols followed. In our experiments, rats 
were treated with captopril and in the referenced studies, hearts were perfused with 
captopril. In our experiments, captopril improved recovery of the left ventricular 
developed pressure (Figure 4.14), but not the rate pressure product (Figure 4.15). Chronic 
treatment with O. africana extract had no effect on cardiac function and infarct size. The 
findings of this study, suggest that chronic treatment with O. africana extract in our 
experimental setting does not improve cardiac function and also does not have an effect 
on infarct size and this may be due to loss of PKB activation in our experimental setting 
(cf. page 63). 
 
5.5 Effect of chronic treatment with O. africana extract, captopril and 
jelly extract on PKB / Akt 
 
Our experiments were based on the hypothesis that ACE inhibitors, by decreasing AII 
levels, increase PI-3-kinase activity, required for PKB phosphorylation. The crude 
aqueous extract of the O. africana leaves decreases plasma AII levels in hypertensive rats 
(Wang, 2008). In rats treated with O. africana extract and subjected to ischemia-
reperfusion, the extract had no effect on PKB / Akt phosphorylation. We, therefore, 
treated rats for 5 weeks with O. africana extract and isolated the hearts without perfusing 
them. This was to determine whether chronic treatment would activate the PKB / Akt 
protein in cardiac tissue in vivo. Captopril and the jelly (vehicle for captopril) groups 
were also added.  
 
Our results showed that chronic treatment with O. africana extract and captopril had no 
effect on PKB / Akt, although there was a 3-fold increase in PKB / Akt phosphorylation. 
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The fact that the 3-fold increase in PKB / Akt was not statistical significant may be due to 
the small sample size used for the Western blot experiments (Figure 4.19B).  
 
5.6 Conclusion 
The results of this study showed that treatment with the crude aqueous extract of O. 
africana leaves did not protect against ischemia-reperfusion injury in the isolated 
perfused rat heart.  
 
5.7 Recommendations 
We have demonstrated that chronic treatment with the crude aqueous extract of the O. 
africana is not cardioprotective against ischemia-reperfusion injury on isolated perfused 
heart in our experimental setting. When the plant extract was present in the blood (non-
perfused hearts), there was a 3-fold increase in PKB / Akt phosphorylation, although this 
was not statistical significant because of the small sample size used for the Western blot 
experiments. In future experiments, an in vivo model of ischemia-reperfusion should thus 
be used. One can then also use leaves harvested in different seasons to determine whether 
there is a seasonal effect. 
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APPENDIX 
 
Appendix Ι. Regression analysis of dose-response relationship between log transformed 
doses of the aqueous extract of O. africana and % lethality 
 
 
 
The table was taken from Graph Pad Prism (version 5.02; http://www.graphpad.com), the 
program in which the regression analysis was performed. The LC50
 
 of the aqueous 
extract of O. africana was 1269 mg/ml and the associated 95% confidence interval was 
1016 to 1586 mg/ml. 
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